Terms: = Colorectal cancer AND ERCC4, XPF, 2072, ENSG00000175595, Q92889 AND Treatment
11 results:
1. ercc4: a potential regulatory factor in inflammatory bowel disease and inflammation-associated colorectal cancer.
Shi R; Wang S; Jiang Y; Zhong G; Li M; Sun Y
Front Endocrinol (Lausanne); 2024; 15():1348216. PubMed ID: 38516408
[TBL] [Abstract] [Full Text] [Related]
2. The ZEB2-dependent EMT transcriptional programme drives therapy resistance by activating nucleotide excision repair genes ERCC1 and ercc4 in colorectal cancer.
Sreekumar R; Al-Saihati H; Emaduddin M; Moutasim K; Mellone M; Patel A; Kilic S; Cetin M; Erdemir S; Navio MS; Lopez MA; Curtis N; Yagci T; Primrose JN; Price BD; Berx G; Thomas GJ; Tulchinsky E; Mirnezami A; Sayan AE
Mol Oncol; 2021 Aug; 15(8):2065-2083. PubMed ID: 33931939
[TBL] [Abstract] [Full Text] [Related]
3. The value of KRAS gene status in predicting local tumor progression of colorectal liver metastases following radiofrequency ablation.
Jiang BB; Yan K; Zhang ZY; Yang W; Wu W; Yin SS; Chen MH
Int J Hyperthermia; 2019 Jan; 36(1):211-219. PubMed ID: 30663903
[TBL] [Abstract] [Full Text] [Related]
4. Interrogation of ethnomedicinal plants for synthetic lethality effects in combination with deficiency in the DNA repair endonuclease RAD1 using a yeast cell-based assay.
Aung HM; Huangteerakul C; Panvongsa W; Jensen AN; Chairoungdua A; Sukrong S; Jensen LT
J Ethnopharmacol; 2018 Sep; 223():10-21. PubMed ID: 29777901
[TBL] [Abstract] [Full Text] [Related]
5. Line-assisted complete closure for a large mucosal defect after colorectal endoscopic submucosal dissection decreased post-electrocoagulation syndrome.
Yamasaki Y; Takeuchi Y; Iwatsubo T; Kato M; Hamada K; Tonai Y; Matsuura N; Kanesaka T; Yamashina T; Arao M; Suzuki S; Shichijo S; Nakahira H; Akasaka T; Hanaoka N; Higashino K; Uedo N; Ishihara R; Okada H; Iishi H
Dig Endosc; 2018 Sep; 30(5):633-641. PubMed ID: 29573468
[TBL] [Abstract] [Full Text] [Related]
6. Enhancement of oxaliplatin sensitivity in human colorectal cancer by hypericin mediated photodynamic therapy via ROS-related mechanism.
Lin S; Lei K; Du W; Yang L; Shi H; Gao Y; Yin P; Liang X; Liu J
Int J Biochem Cell Biol; 2016 Feb; 71():24-34. PubMed ID: 26673998
[TBL] [Abstract] [Full Text] [Related]
7. Association between ERCC1 and xpf polymorphisms and risk of colorectal cancer.
Yang H; Li G; Li WF
Genet Mol Res; 2015 Jan; 14(1):700-5. PubMed ID: 25730007
[TBL] [Abstract] [Full Text] [Related]
8. Association of single nucleotide polymorphisms of ERCC1 and xpf with colorectal cancer risk and interaction with tobacco use.
Hou R; Liu Y; Feng Y; Sun L; Shu Z; Zhao J; Yang S
Gene; 2014 Sep; 548(1):1-5. PubMed ID: 24861646
[TBL] [Abstract] [Full Text] [Related]
9. An explorative analysis of ERCC1-19q13 copy number aberrations in a chemonaive stage III colorectal cancer cohort.
Smith DH; Christensen IJ; Jensen NF; Markussen B; Müller S; Nielsen HJ; Brünner N; Nielsen KV
BMC Cancer; 2013 Oct; 13():489. PubMed ID: 24144331
[TBL] [Abstract] [Full Text] [Related]
10. Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers.
Stevens EV; Nishizuka S; Antony S; Reimers M; Varma S; Young L; Munson PJ; Weinstein JN; Kohn EC; Pommier Y
Mol Cancer Ther; 2008 Jan; 7(1):10-8. PubMed ID: 18187810
[TBL] [Abstract] [Full Text] [Related]
11. Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab.
Prewett M; Deevi DS; Bassi R; Fan F; Ellis LM; Hicklin DJ; Tonra JR
Clin Cancer Res; 2007 Dec; 13(24):7432-40. PubMed ID: 18094427
[TBL] [Abstract] [Full Text] [Related]
